112 related articles for article (PubMed ID: 8453691)
1. Evidence of an absorption phase after short intravenous suramin infusions.
Hutson PR; Tutsch K; Spriggs D; Christian M; Rago R; Mutch R; Wilding G
Cancer Chemother Pharmacol; 1993; 31(6):495-9. PubMed ID: 8453691
[TBL] [Abstract][Full Text] [Related]
2. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
3. Suramin as a chemosensitizer: oral pharmacokinetics in rats.
Ogden A; Wientjes MG; Au JL
Pharm Res; 2004 Nov; 21(11):2058-63. PubMed ID: 15587928
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
6. Adaptive control with feedback strategies for suramin dosing.
Cooper MR; Lieberman R; La Rocca RV; Gernt PR; Weinberger MS; Headlee DJ; Kohler DR; Goldspiel BR; Peck CC; Myers CE
Clin Pharmacol Ther; 1992 Jul; 52(1):11-23. PubMed ID: 1623689
[TBL] [Abstract][Full Text] [Related]
7. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
8. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Hutson PR; Tutsch KD; Rago R; Arzoomanian R; Alberti D; Pomplun M; Church D; Marnocha R; Cheng AL; Kehrli N; Wilding G
Clin Cancer Res; 1998 Jun; 4(6):1429-36. PubMed ID: 9626459
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
[TBL] [Abstract][Full Text] [Related]
11. Suramin: rapid loading and weekly maintenance regimens for cancer patients.
van Rijswijk RE; van Loenen AC; Wagstaff J; Meijer E; Lopez R; van Groeningen CJ; Heimans JJ; Pinedo HM
J Clin Oncol; 1992 Nov; 10(11):1788-94. PubMed ID: 1403059
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
[TBL] [Abstract][Full Text] [Related]
14. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
15. Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Chen D; Song SH; Wientjes MG; Yeh TK; Zhao L; Villalona-Calero M; Otterson GA; Jensen R; Grever M; Murgo AJ; Au JL
Pharm Res; 2006 Jun; 23(6):1265-74. PubMed ID: 16715360
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
17. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
[TBL] [Abstract][Full Text] [Related]
18. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
19. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.
Mross K; Hüttmann A; Herbst K; Hanauske AR; Schilling T; Manegold C; Burk K; Hossfeld DK
Cancer Chemother Pharmacol; 1996; 38(3):217-24. PubMed ID: 8646795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
